Skip to main content
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
letter
. 2026 Oct 30;123(46):e2630263123. doi: 10.1073/pnas.2630263123

Evidence and gaps in the proposed ALDH9A1–carnitine–acetyl-CoA–IL-1β axis

Tao Yu a, Wanjun Yu a,1
PMCID: PMC13778521  PMID: 42961962

Du et al. (1) combine multiomics analyses, genetic perturbation, in vivo experiments, and IL-1β neutralization to implicate ALDH9A1 in immunotherapy resistance in non–small-cell lung cancer. Their findings support functional associations involving ALDH9A1, acetyl-CoA, and IL-1β-related phenotypes, but the proposed role of carnitine as the necessary intermediate remains insufficiently established.

We could not identify compound-resolved measurements of free carnitine, γ-butyrobetaine, 4-trimethylaminobutyraldehyde, or clearly annotated total carnitine and acylcarnitine pools in the main text or SI Appendix. Although Fig. 1L of ref. 1 refers to ‘multiple carnitine-related metabolites,’ their chemical identities, annotation confidence, and quantitative values are not clearly reported. Without compound-level validation and targeted quantification, these signals cannot be taken as direct evidence of increased free-carnitine abundance or increased flux through carnitine biosynthesis.

ALDH9A1 catalyzes the oxidation of 4-trimethylaminobutyraldehyde to γ-butyrobetaine, a canonical step in carnitine biosynthesis (2–4). This position provides a rationale for studying ALDH9A1, but it does not by itself establish ALDH9A1 as a committed or rate-controlling step in NSCLC cells. Increased ALDH9A1 expression alone does not demonstrate increased intracellular free-carnitine abundance or pathway flux, as these depend on substrate availability, downstream enzyme activity, transport, and cellular carnitine handling.

The reported acetyl-CoA measurements support associations with ALDH9A1 perturbation and IL-1β phenotypes, but do not establish that carnitine is a necessary intermediate. Carnitine can reversibly buffer acetyl groups through acetylcarnitine formation. Thus, altered acetyl-CoA levels do not on their own demonstrate carnitine dependence. The data also do not exclude alternative effects of ALDH9A1 perturbation on aldehyde metabolism, mitochondrial acetyl-group handling, or related processes.

Targeted measurements of carnitine, γ-butyrobetaine, and acylcarnitine species, together with carnitine add-back and stable-isotope tracing from labeled trimethyllysine and/or γ-butyrobetaine, would help determine whether altered carnitine biosynthetic flux contributes to the acetyl-CoA and IL-1β phenotypes. Rescue of ALDH9A1-loss phenotypes by carnitine, particularly when accompanied by restoration of acetylcarnitine flux, would provide stronger evidence for mediation.

The current results therefore support a biologically plausible model linking ALDH9A1 to acetyl-CoA and IL-1β-related phenotypes, but do not yet establish carnitine as the causal mediator. We suggest presenting the ALDH9A1–carnitine–acetyl-CoA–IL-1β relationship as a hypothesis-generating model rather than as a fully validated linear causal axis. Fig. 1 illustrates the evidence gaps in this proposed model.

Fig. 1.

Three-panel figure with flowcharts labeled A, B, and C showing metabolic links between ALDH9A1, carnitine, acetyl-CoA, and IL-1β-related phenotypes.

Reported associations and unresolved causal links in the proposed ALDH9A1–carnitine–acetyl-CoA–IL-1β model. (A) Relationships reported by Du et al. are shown as associations rather than as a complete causal pathway. (B) The established, reversible CRAT-catalyzed transfer of an acetyl group between acetyl-CoA and carnitine is shown as proposed metabolic context; its engagement in the NSCLC model has not been directly established. (C) Key unresolved questions include whether carnitine-dependent flux is required for the ALDH9A1–acetyl-CoA relationship and whether changes in carnitine or acetylcarnitine causally affect the inflammatory phenotype. Solid arrows indicate reported associations; dashed arrows in the proposed-context color indicate established biochemical relationships used as mechanistic context; dashed arrows in the unresolved color indicate causal or model-specific links that remain untested.

Acknowledgments

Data, Materials, and Software Availability

There are no data underlying this work.

Author contributions

T.Y. and W.Y. designed research; and wrote the paper.

Competing interests

The authors declare no competing interest.

References

  • 1.Du H., et al. , Single-cell multiomics identifies an ALDH9A1–carnitine signaling axis driving resistance of NSCLC to immunotherapy. Proc. Natl. Acad. Sci. U.S.A. 123, e2535328123 (2026). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Wyatt J. W., et al. , Inhibition, crystal structures, and in-solution oligomeric structure of aldehyde dehydrogenase 9A1. Arch. Biochem. Biophys. 691, 108477 (2020). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Vaz F. M., Wanders R. J., Carnitine biosynthesis in mammals. Biochem. J. 361, 417–429 (2002). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Li X., et al. , Biallelic variants in BBOX1 cause L-carnitine deficiency and elevated γ-butyrobetaine. NPJ Genom. Med. 10, 64 (2025). [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

There are no data underlying this work.


Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES